Related Experiment Video
Updated: Feb 6, 2026

Chuzhen Therapy as a Non-Invasive Traditional Chinese Therapy for Neck Pain
Published on: June 6, 2025
Fenofibrate and Dyslipidemia: Still a Place in Therapy?
Nicola Tarantino1, Francesco Santoro1,2, Michele Correale3
1Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
Abstract:
Dyslipidemia is one of the major cardiovascular risk factors, but beyond statin treatment-which represents the cornerstone of therapy-a relevant practical uncertainty regards the use of fibrate derivatives. In the lack of successful results from the main cardiovascular trials, guidelines recommend the use of peroxisome proliferator-activated receptor agonists in selected cases, i.e. patients with true atherogenic dyslipidemia. However, recent observations indicate that fenofibrate treatment may provide a reliable complementary support against residual cardiovascular risk. We therefore summarize current evidence on fenofibrate, seeking to provide an updated interpretation of recent studies in the field.
Insights
Fenofibrate may offer additional cardiovascular protection beyond statins for patients with atherogenic dyslipidemia. This review examines current evidence on fenofibrate
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Dyslipidemia is a key cardiovascular risk factor.
- Statin therapy is the primary treatment.
- Uncertainty exists regarding the use of fibrates.
Purpose of the Study:
- To review current evidence on fenofibrate.
- To interpret recent studies on fenofibrate's role in cardiovascular risk.
- To address the use of peroxisome proliferator-activated receptor agonists.
Main Methods:
- Literature review of recent studies on fenofibrate.
- Analysis of clinical trial data.
- Interpretation of evidence regarding residual cardiovascular risk.
Main Results:
- Guidelines recommend peroxisome proliferator-activated receptor agonists for specific cases.
- Fenofibrate shows potential as complementary therapy for residual cardiovascular risk.
- Recent observations support fenofibrate's efficacy.
Conclusions:
- Fenofibrate may be a valuable option for managing atherogenic dyslipidemia.
- Further interpretation of fenofibrate's role in reducing residual cardiovascular risk is warranted.
- Evidence supports fenofibrate's complementary role in cardiovascular risk management.
Related Concept Videos
Gene Therapy
Group Therapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...
Drug Therapy
Antianxiety Medications
Cognitive Therapy

